QCG
ONC

Quadrant Capital Group’s BeOne Medicines Ltd ONC Stock Holding History

Quadrant Capital Group’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$794K Buy
2,673
+27
+1% +$8.74K 0.02% 668
2025
Q4 		$804K Buy
2,646
+22
+0.8% +$7.2K 0.02% 660
2025
Q3 		$894K Buy
2,624
+20
+0.8% +$6.07K 0.03% 566
2025
Q2 		$630K Buy
2,604
+2,377
+1,047% +$583K 0.02% 730
2025
Q1 		$61.8K Buy
227
+18
+9% +$4.21K ﹤0.01% 1649
2024
Q4 		$38.6K Buy
209
+67
+47% +$13.7K ﹤0.01% 1560
2024
Q3 		$31.9K Buy
142
+79
+125% +$14.2K ﹤0.01% 1696
2024
Q2 		$8.99K Sell
63
-23
-27% -$3.54K ﹤0.01% 2153
2024
Q1 		$13.4K Sell
86
-28
-25% -$4.51K ﹤0.01% 1996
2023
Q4 		$20.6K Sell
114
-1
-0.9% -$181 ﹤0.01% 1812
2023
Q3 		$20.7K Buy
115
+3
+3% +$594 ﹤0.01% 1696
2023
Q2 		$20K Sell
112
-2
-2% -$461 ﹤0.01% 1716
2023
Q1 		$24.6K Buy
114
+4
+4% +$959 ﹤0.01% 1586
2022
Q4 		$24.2K Buy
110
+63
+134% +$11.6K ﹤0.01% 1569
2022
Q3 		$6K Buy
47
+26
+124% +$4.46K ﹤0.01% 2107
2022
Q2 		$3K Sell
21
-16
-43% -$2.5K ﹤0.01% 2160
2022
Q1 		$7K Sell
37
-258
-87% -$54.8K ﹤0.01% 1818
2021
Q4 		$80K Sell
295
-19
-6% -$6.42K 0.01% 749
2021
Q3 		$114K Buy
314
+88
+39% +$28.8K 0.02% 573
2021
Q2 		$78K Buy
226
+41
+22% +$13.6K 0.01% 692
2021
Q1 		$64K Sell
185
-55
-23% -$18.2K 0.01% 727
2020
Q4 		$62K Sell
240
-68
-22% -$18.7K 0.01% 685
2020
Q3 		$88K Buy
308
+136
+79% +$32K 0.02% 466
2020
Q2 		$32K Sell
172
-952
-85% -$155K 0.01% 892
2020
Q1 		$139K Buy
1,124
+961
+590% +$150K 0.02% 471
2019
Q4 		$25K Sell
163
-185
-53% -$30.7K ﹤0.01% 1643
2019
Q3 		$42K Sell
348
-147
-30% -$19.5K 0.01% 1297
2019
Q2 		$60K Buy
495
+131
+36% +$16.6K 0.01% 1136
2019
Q1 		$47K Buy
364
+207
+132% +$27.9K 0.01% 1263
2018
Q4 		$22K Buy
+157
New +$20.8K 0.01% 1156

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Quadrant Capital Group's ONC Position: Q1 2026 in Review

Quadrant Capital Group increased its BeOne Medicines Ltd (ONC) stake by 1% in Q1 2026, buying an estimated $8.74K and bringing the position to 2,673 shares worth $794K. The position accounts for 0.02% of the portfolio, ranked #668.

Quadrant Capital Group first reported a position in ONC in Q4 2018 and has held it in 30 quarters since. The position peaked at $894K in Q3 2025. 281 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • Quadrant Capital Group held 2,673 shares of BeOne Medicines Ltd worth $794K as of Q1 2026.
  • Quadrant Capital Group bought 27 BeOne Medicines Ltd shares in Q1 2026, an estimated $8.74K.
  • BeOne Medicines Ltd made up 0.02% of Quadrant Capital Group's portfolio in Q1 2026, its #668 holding.
  • Quadrant Capital Group first reported a position in BeOne Medicines Ltd in Q4 2018 and has held it in 30 quarters since.
  • Quadrant Capital Group's BeOne Medicines Ltd position peaked at $894K in Q3 2025.
  • 281 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.